CN Patent

CN101686988A — 含有达格列嗪丙二醇水合物的药物制剂

Assigned to AstraZeneca AB · Expires 2010-03-31 · 16y expired

What this patent protects

本发明提供口服用胶囊或片剂形式的药物制剂，其包含式(Ia)或式(Ib)的达格列嗪丙二醇水合物和药学上可接受的载体，该制剂被设计用于速释。该制剂用于治疗糖尿病和相关疾病。

USPTO Abstract

本发明提供口服用胶囊或片剂形式的药物制剂，其包含式(Ia)或式(Ib)的达格列嗪丙二醇水合物和药学上可接受的载体，该制剂被设计用于速释。该制剂用于治疗糖尿病和相关疾病。

Drugs covered by this patent

Patent Metadata

Patent number
CN101686988A
Jurisdiction
CN
Classification
—
Expires
2010-03-31
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.